Sonoma Pharmaceuticals, Inc. (SNOA) Income Statement
SNOA FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsSNOA revenue and net income
Where SNOA's revenue goes
FY2026Each bar shows an amount and its share of revenue. SNOA kept −16.3% of revenue as net income.
SNOA profit margins
SNOA growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +36.7% | +13.7% | +0.9% | +7.6% |
| Gross profit | +35.7% | +18.3% | +2.5% | +10.8% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SNOA quarterly EPS vs estimates
Sonoma Pharmaceuticals beat the analyst EPS estimate in 2 of the last 6 quarters. Next report: November 3, 2026.
SNOA income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M | $18.6M | $17.9M | $19.0M | $16.7M | $12.8M |
| Cost of revenue | $12.1M | $8.8M | $8.0M | $8.8M | $8.6M | $12.1M | $9.8M | $10.1M | $9.3M | $7.2M |
| Gross profit | $7.4M | $5.5M | $4.7M | $4.5M | $4.0M | $6.6M | $8.1M | $8.9M | $7.3M | $5.7M |
| Research & development | $2.3M | $1.8M | $1.9M | $207,000 | $125,000 | $555,000 | $1.3M | $1.5M | $1.6M | $1.6M |
| Sales, general & admin | $7.6M | $7.4M | $7.6M | $8.8M | $9.8M | $9.5M | $13.7M | $18.8M | $20.1M | $17.2M |
| Total operating expenses | $9.9M | $9.2M | $9.4M | $9.0M | $9.9M | $10.0M | $15.5M | $20.1M | $21.5M | $18.6M |
| Operating income | −$2.5M | −$3.7M | −$4.7M | −$4.6M | −$5.9M | −$3.4M | −$7.4M | −$11.3M | −$14.2M | −$13.0M |
| Interest income | — | — | — | — | — | $16,000 | $50,000 | $190,000 | $258,000 | $22,000 |
| Interest expense | — | — | — | $16,000 | $10,000 | $12,000 | $16,000 | $33,000 | $40,000 | $3,000 |
| Income before taxes | −$3.4M | −$2.9M | −$5.0M | −$5.2M | −$5.4M | −$3.9M | −$3.5M | −$11.3M | −$14.3M | −$12.9M |
| Income taxes | −$244,000 | $550,000 | −$196,000 | −$33,000 | −$332,000 | $713,000 | $29,000 | $458,000 | $50,000 | −$4.3M |
| Net income | −$3.2M | −$3.5M | −$4.8M | −$5.2M | −$5.1M | −$4.0M | −$3.3M | −$11.8M | −$14.3M | $9.3M |
| EBITDA | −$2.3M | −$2.8M | −$4.9M | −$5.1M | −$5.2M | −$3.2M | −$3.2M | −$10.9M | −$13.7M | −$12.7M |
| EPS (diluted) | −$1.32 | −$3.10 | −$7.75 | −$2.42 | −$16.37 | −$0.24 | −$32.57 | −$226.52 | −$407.97 | $575.19 |
| Gross margin | 38.0% | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% |
| Operating margin | −12.6% | −26.0% | −36.9% | −34.4% | −46.6% | −18.5% | −41.2% | −59.3% | −85.2% | −101.2% |
| Net margin | −16.3% | −24.2% | −38.0% | −38.8% | −40.3% | −21.2% | −18.5% | −62.2% | −86.0% | 72.3% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $5.6M | $4.3M | $5.6M | $4.0M | $3.8M | $3.6M | $3.6M | $3.4M | $3.4M | $3.1M | $2.7M |
| Cost of revenue | $3.8M | $3.4M | $2.7M | $3.5M | $2.6M | $2.2M | $2.3M | $2.2M | $2.1M | $2.3M | $1.7M | $1.7M |
| Gross profit | $2.6M | $2.2M | $1.6M | $2.1M | $1.5M | $1.5M | $1.3M | $1.4M | $1.3M | $1.1M | $1.5M | $990,000 |
| Research & development | $597,000 | $545,000 | $557,000 | $575,000 | $594,000 | $411,000 | $427,000 | $506,000 | $470,000 | $409,000 | $601,000 | $536,000 |
| Sales, general & admin | $2.0M | $2.0M | $1.8M | $1.9M | $2.0M | $1.8M | $1.9M | $1.7M | $2.0M | $2.1M | $1.7M | $1.7M |
| Total operating expenses | $2.6M | $2.5M | $2.3M | $2.5M | $2.6M | $2.2M | $2.3M | $2.2M | $2.5M | $2.5M | $2.3M | $2.2M |
| Operating income | −$40,000 | −$351,000 | −$678,000 | −$337,000 | −$1.1M | −$656,000 | −$1.0M | −$850,000 | −$1.2M | −$1.4M | −$844,000 | −$1.2M |
| Income before taxes | −$330,000 | −$497,000 | −$949,000 | −$731,000 | −$1.2M | −$528,000 | −$919,000 | −$463,000 | −$997,000 | −$1.4M | −$923,000 | −$1.3M |
| Income taxes | — | $84,000 | −$130,000 | −$197,000 | −$1,000 | $248,000 | $9,000 | $147,000 | $146,000 | −$292,000 | −$57,000 | $186,000 |
| Net income | −$330,000 | −$581,000 | −$819,000 | −$534,000 | −$1.2M | −$776,000 | −$928,000 | −$610,000 | −$1.1M | −$1.1M | −$866,000 | −$1.5M |
| EBITDA | −$298,000 | −$318,000 | −$644,000 | −$301,000 | −$1.1M | −$625,000 | −$998,000 | −$815,000 | −$1.1M | −$1.3M | −$878,000 | −$1.3M |
| EPS (diluted) | $0.02 | −$0.15 | −$0.48 | −$0.32 | −$0.37 | −$0.48 | −$0.63 | −$0.59 | −$1.40 | −$0.07 | −$1.60 | −$5.80 |
| Gross margin | 40.2% | 39.2% | 37.9% | 37.8% | 36.5% | 40.7% | 35.6% | 38.0% | 38.5% | 31.7% | 46.5% | 36.3% |
| Operating margin | −0.6% | −6.3% | −15.6% | −6.0% | −27.3% | −17.5% | −28.9% | −23.7% | −34.6% | −41.0% | −26.9% | −44.2% |
| Net margin | −5.2% | −10.4% | −18.8% | −9.5% | −30.9% | −20.7% | −26.0% | −17.0% | −33.7% | −31.0% | −27.6% | −54.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SNOA's financial statements (latest annual report filed June 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SNOA financial results
In fiscal year 2026 (ended March 31, 2026), Sonoma Pharmaceuticals reported revenue of $19.5 million, up 36.7% from the year before. It had a net loss of $3.2 million, a net profit margin of −16.3%. Diluted earnings per share came to −$1.32. Over five years revenue grew at an average rate of 0.9% a year.
See the SNOA stock overview for the latest quote and news, or the SNOA chart for price history and technical indicators.
SNOA income statement FAQ
What is Sonoma Pharmaceuticals's annual revenue?
Sonoma Pharmaceuticals reported total revenue of $19.5 million for fiscal year 2026, which ended on March 31, 2026. That was up 36.7% from $14.3 million the previous year.
Is Sonoma Pharmaceuticals profitable?
No. Sonoma Pharmaceuticals reported a net loss of $3.2 million in fiscal 2026, a net profit margin of −16.3%; its operating margin was −12.6%.
What is Sonoma Pharmaceuticals's gross margin?
Sonoma Pharmaceuticals's gross margin was 38.0% in fiscal 2026: for every $100 of revenue, Sonoma Pharmaceuticals kept $38 after the direct cost of its products and services.
How much does Sonoma Pharmaceuticals spend on research and development?
Sonoma Pharmaceuticals spent $2.3 million on research and development in fiscal 2026, 11.6% of revenue.
How fast is Sonoma Pharmaceuticals growing?
Revenue grew 0.9% a year on average over the last five fiscal years, from $18.6 million to $19.5 million.
What are Sonoma Pharmaceuticals's earnings per share?
Sonoma Pharmaceuticals earned $-1.32 per diluted share in fiscal 2026, compared with $-3.10 a year earlier.
When will Sonoma Pharmaceuticals report its next earnings?
Sonoma Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026.
When does Sonoma Pharmaceuticals's fiscal year end?
Sonoma Pharmaceuticals's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on June 16, 2026.